DELUCCIA ROBERT J 4

What Happened

• Robert J. DeLuccia, a director of Acurx Pharmaceuticals (ACXP), received a grant of stock options to purchase 37,100 shares on April 20, 2026. The Form 4 reports the transaction as an award/derivative (code A) with a reported price of $0.00 (this reflects an option grant, not a market purchase).

Key Details

• Transaction date: 2026-04-20; Filing date: 2026-04-22 (filed two days after the grant; appears timely).
• Grant size: options to purchase 37,100 shares; reported amount/value shown as $0.00 on the Form 4 because this is a derivative award.
• Vesting: options vest in 36 equal monthly installments beginning on the grant date (3-year monthly vesting).
• Shares owned after transaction: not specified in the supplied filing details.
• Transaction code: A (award/grant). This was a grant of options, not an exercise or sale.

Context

• These are option awards (a form of compensation). No shares were exercised or sold and no cash purchase occurred at the grant.
• Options only have value if the company’s stock rises above the option strike price; the strike price was not provided in the supplied details.
• Such grants are common for executives and directors as retention/compensation and do not alone indicate immediate bullish or bearish trading by the insider.